^
Association details:
| Biomarker: | IGFBP5-L |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | ganitumab (AMG 479) (IGF-1R inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
Published date:
10/05/2021
Excerpt:
...Ganitumab was tested in combination with metformin and paclitaxel (PGM)...In the population as a whole, lower levels of IRS1 and IGFBP5 significantly associated with better response to PGM (LR p < 0.05), as did lower levels of the signature IGF-1 ligand score and higher levels of the IGF-1R signature.
Secondary therapy:
paclitaxel + metformin
DOI:
https://doi.org/10.1038/s41523-021-00337-2
